AZURRX BIOPHARMA, INC. (NASDAQ:AZRX) Files An 8-K Other Events
Item 9.01. Other Events.
AZURRX BIOPHARMA, INC. (NASDAQ:AZRX) Files An 8-K Other Events
On June 7, 2019, AzurRx BioPharma, Inc. (the “Company”) issued a press release announcing that both the United States Patent and Trademark Office and the Japan Patent Office have respectively issued US Patent 10,118,928 and Japan Patent 6512613, for a patent entitled “Treatment of H. Pylori Infections Using MTAN Inhibitors.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01.Financial Statements and Exhibits.
See Exhibit Index.
AzurRx BioPharma, Inc. Exhibit
EX-99.1 2 ex99-1.htm PRESS RELEASE AzurRx BioPharma,…
To view the full exhibit click
EX-99.1 2 ex99-1.htm PRESS RELEASE AzurRx BioPharma,…
To view the full exhibit click
hereAbout AZURRX BIOPHARMA, INC. (NASDAQ:AZRX)
AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).
